Retatrutide vs Ipamorelin
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
RetatrutideGrowth Hormone Peptides
Ipamorelin- Summary
- Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed an unprecedented average 24% body weight reduction at 48 weeks — exceeding any approved medication to date. It is in Phase 3 trials as of 2024.
- Ipamorelin is a selective GHRP (growth hormone releasing peptide) and one of the cleanest GH secretagogues available. It selectively stimulates GH release without significantly raising cortisol, prolactin, or appetite — making it ideal for long-term use and anti-aging protocols.
- Half-Life
- ~10–12 days
- 2 hours
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg
- 100–300 mcg
- Frequency
- Once weekly
- Once to twice daily
- Key Benefits
- ~24% body weight reduction at 48 weeks in Phase 2 (highest dose)
- Superior to both semaglutide and tirzepatide in early trial comparisons
- Triple receptor mechanism addresses multiple obesity pathways
- Significant reduction in liver fat (MASH/NAFLD indication being studied)
- Improved cardiovascular and metabolic markers
- Once-weekly dosing
- Potential for greatest weight loss of any currently investigated compound
- Increases lean muscle mass
- Enhances fat loss
- Improves recovery time
- Strengthens bones and joints
- Better sleep quality and REM sleep
- Enhanced skin elasticity
- Minimal impact on hunger or cortisol
- No cortisol or prolactin spike
- Clean GH release suitable for long-term protocols
- Side Effects
- Nausea and vomiting (common during titration, similar to semaglutide/tirzepatide)
- Diarrhea
- Constipation
- Heart rate increase (from glucagon receptor agonism)
- +2 more
- Injection site irritation
- Temporary water retention (mild)
- Possible hunger increase (milder than GHRP-6)
- Numbness or tingling in extremities (rare)
- Stacks With
- —
- —